TY - JOUR
T1 - International intraductal papillary mucinous neoplasms registry
T2 - Long-term results based on the new guidelines
AU - Moris, Maria
AU - Raimondo, Massimo
AU - Woodward, Timothy A.
AU - Skinner, Verna J.
AU - Arcidiacono, Paolo G.
AU - Petrone, Maria C.
AU - De Angelis, Claudio
AU - Manfrè, Selene
AU - Carrara, Silvia
AU - Jovani, Manol
AU - Fusaroli, Pietro
AU - Wallace, Michael B.
N1 - Publisher Copyright:
Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2017/3/1
Y1 - 2017/3/1
N2 - Objective: The aim of this studywas to analyze the outcomes of a long-term intraductal papillary mucinous neoplasm (IPMN) registry and evaluate new guidelines. Methods: A prospectively maintained IPMN registry involving 6 centers in Europe and the United States was used to collect the data. Patients with more than 1-year follow-up and no malignancy diagnosed within the first 3 months of surveillance were included. Results: From 1999 to 2014, 620 patients were included. The median follow-up time was 3 years. Thirty-seven (6%) patients developed malignancy with a median time from IPMN diagnosis to malignancy of 10.3 months. The 1-, 5-, and 10-year actuarial rates of disease-free survival were 97%, 93%, and 92% respectively. Four hundred thirty-one patients met criteria for low-risk branch duct IPMNconsisting of cyst size less than 3 cm, with no solid component or main duct dilation. Eight malignancies were diagnosed in this subgroup, all of them within the first 5 years. From this subcohort, 112 patients had a follow-up time ofmore than 5 years, and no malignancy was diagnosed. Conclusions: In IPMN lesions with low-risk features at baseline, the risk of progression tomalignancy after the first 5 years of follow-up wasminimal. Furthermore, the main cyst characteristics remained unchanged during their surveillance.
AB - Objective: The aim of this studywas to analyze the outcomes of a long-term intraductal papillary mucinous neoplasm (IPMN) registry and evaluate new guidelines. Methods: A prospectively maintained IPMN registry involving 6 centers in Europe and the United States was used to collect the data. Patients with more than 1-year follow-up and no malignancy diagnosed within the first 3 months of surveillance were included. Results: From 1999 to 2014, 620 patients were included. The median follow-up time was 3 years. Thirty-seven (6%) patients developed malignancy with a median time from IPMN diagnosis to malignancy of 10.3 months. The 1-, 5-, and 10-year actuarial rates of disease-free survival were 97%, 93%, and 92% respectively. Four hundred thirty-one patients met criteria for low-risk branch duct IPMNconsisting of cyst size less than 3 cm, with no solid component or main duct dilation. Eight malignancies were diagnosed in this subgroup, all of them within the first 5 years. From this subcohort, 112 patients had a follow-up time ofmore than 5 years, and no malignancy was diagnosed. Conclusions: In IPMN lesions with low-risk features at baseline, the risk of progression tomalignancy after the first 5 years of follow-up wasminimal. Furthermore, the main cyst characteristics remained unchanged during their surveillance.
KW - IPMN
KW - Long-term analysis
KW - Malignancy
UR - http://www.scopus.com/inward/record.url?scp=85009808665&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85009808665&partnerID=8YFLogxK
U2 - 10.1097/MPA.0000000000000750
DO - 10.1097/MPA.0000000000000750
M3 - Article
C2 - 28099263
AN - SCOPUS:85009808665
SN - 0885-3177
VL - 46
SP - 306
EP - 310
JO - Pancreas
JF - Pancreas
IS - 3
ER -